Sana Biotechnology (SANA) Expected to Announce Quarterly Earnings on Thursday

Sana Biotechnology (NASDAQ:SANA) will likely be announcing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of ($0.1478) per share for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:00 PM ET.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.02. On average, analysts expect Sana Biotechnology to post ($0.72) EPS for the current fiscal year and ($0.61) EPS for the next fiscal year.

Sana Biotechnology Stock Up 1.7%

NASDAQ SANA opened at $2.44 on Wednesday. Sana Biotechnology has a 12-month low of $2.22 and a 12-month high of $5.49. The company has a market capitalization of $730.44 million, a PE ratio of -3.21 and a beta of 2.30. The firm’s 50 day moving average is $2.98 and its 200-day moving average is $3.38.

Wall Street Analyst Weigh In

Several research analysts recently commented on SANA shares. Bank of America reduced their target price on shares of Sana Biotechnology from $7.00 to $6.00 and set a “buy” rating for the company in a report on Friday, August 14th. TD Cowen raised shares of Sana Biotechnology to a “strong-buy” rating in a research report on Monday, August 24th. Wall Street Zen lowered shares of Sana Biotechnology from a “hold” rating to a “sell” rating in a research note on Monday, July 20th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Sana Biotechnology in a research report on Wednesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $9.60.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc is a clinical-stage biotechnology company focused on developing engineered cell and gene therapies for serious diseases. The company’s approach is designed to create durable treatments by modifying cells outside or inside the body and using them to replace, repair, or supplement damaged or missing biological functions.

Sana is developing proprietary technologies intended to support the delivery and persistence of therapeutic cells. These include platforms for engineering cells to evade immune-system detection, potentially allowing donor-derived cells to be used without extensive immune suppression, as well as methods for delivering genetic instructions directly to targeted tissues.